Kidney News and Research

RSS

Inhibitex to present INX-189 data for HCV infections at AASLD Meeting

Inhibitex, Inc. announced today that three posters describing preclinical data on INX-189, the Company's nucleotide polymerase inhibitor in clinical development for the treatment of chronic hepatitis C (HCV) infections, will be presented by various scientists from the Company at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston, MA.

2 Nov 2010

Innovative lifesaving device for patients with advanced heart failure

Bradley Cantley, 41, headed home from UC San Diego Medical Center connected to a lifesaving heart machine called a left ventricular assisted device (LVAD). For patients with advanced heart failure, the mechanical pump rapidly improves circulation throughout the body and serves as a bridge to transplant. Cantley is the first of many patients, locally and globally, who will benefit from the expanded heart surgery program at UC San Diego Health System.

2 Nov 2010

Eli Lilly's new research center to focus on diabetes in China

Eli Lilly and Company announced today plans to open a research center focused on diabetes in China, where the incidence of the disease has reached epidemic proportions.

2 Nov 2010

Researchers investigate Human-cl rhFVIII factor for severe hemophilia A treatment

Octapharma AG, one of the largest human protein products manufacturers in the world, and Octapharma USA today announced that patients diagnosed with severe hemophilia A have started treatment in a multi-center study that is researching the use of the first recombinant Factor VIII (rFVIII) derived from a human cell line (Human-cl rhFVIII).

2 Nov 2010

NICE to lose its power to ban life saving drugs

Ministers have finally clarified that patients would not be denied life-extending drugs just because the NHS rationing body decides they are too expensive. National Institute for Health and Clinical Excellence (NICE) the drug watchdog in the UK will be stripped of its powers to stop drugs being available on the NHS due to price. The arbitrary limit on the cost of new drugs – around £30,000 per year of extended high-quality life – will be scrapped from 2014.

1 Nov 2010

FDA approves cancer drug Afinitor for treatment of rare genetic disorder

The U.S. Food and Drug Administration approved the cancer drug Afinitor (everolimus) on Friday to treat patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis (TS), a rare genetic disorder. This approval was for treatments of SEGA that can not be treated with surgery.

1 Nov 2010

New laboratory-engineered livers could provide solution to donor shortage

Researchers at the Institute for Regenerative Medicine at Wake Forest University Baptist Medical Center have reached an early, but important, milestone in the quest to grow replacement livers in the lab. They are the first to use human liver cells to successfully engineer miniature livers that function - at least in a laboratory setting like human livers. The next step is to see if the livers will continue to function after transplantation in an animal model.

1 Nov 2010

Gilead to present data of two Phase III trials evaluating Viread efficacy for HBV infection at The Liver Meeting 2010

Gilead Sciences, Inc. today announced new data from the open-label phase of two pivotal Phase III clinical trials (Studies 102 and 103) evaluating the four-year efficacy of Viread (tenofovir disoproxil fumarate) for the treatment of chronic hepatitis B virus (HBV) infection.

1 Nov 2010

UK HealthCare transplant recipient wins at 2010 U.S. Transplant Games

One transplant recipient from UK HealthCare, Dan Gutenson of Stanford, Ky., joined the 36 other members of "Team Kentucky" in Madison, Wisconsin for the 2010 U.S. Transplant Games this past summer. Gutenson, who received his kidney transplant in Sept. 2009, suffered from polycystic disease and received a kidney from a living donor in the church he pastors in Lincoln County, Ky.

30 Oct 2010

Summit discusses value, cost-effectiveness of America's investment in wellness and prevention

America's historic investment in wellness and prevention mandated under the Affordable Care Act may not always save money – but it will be worth it.

30 Oct 2010

Dysfunction of Grhl2 factor may affect epithelial barrier formation, contribute to congenital abnormalities

Scientists of the Max Delbr-ck Center for Molecular Medicine (MDC) Berlin-Buch and the Experimental and Clinical Research Center (ECRC) of MDC and Charit- in Berlin-Buch have gained new insights into the development of epithelial cells and their molecular repertoire.

30 Oct 2010

AVEO to raise $61 million through private placement

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the execution of a securities purchase agreement with a select group of institutional and accredited investors providing for a private placement, or PIPE financing.

30 Oct 2010

Access to kidney transplantation increases for elderly patients

Elderly patients with kidney failure get kidney transplants more often than they did a decade ago, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society of Nephrology (CJASN). The results suggest that the chances of receiving a kidney transplant are better than ever for an older patient who needs one.

29 Oct 2010

Low birth weight linked to poor growth in children with CKD

The lower the birth weight, the greater the chance of poor growth rate in children with chronic kidney disease (CKD), according to a new study appearing in an upcoming issue of the Clinical Journal of the American Society of Nephrology (CJASN).

29 Oct 2010

Antigenics third quarter net loss decreases from $10.8 million to $5.9 million

Antigenics Inc. reported today its results for the quarter ended September 30, 2010. The company incurred a net loss attributable to common stockholders of $5.9 million, or $0.06 per share, basic and diluted, for the third quarter of 2010, compared with a net loss attributable to common stockholders of $10.8 million, or $0.13 per share, basic and diluted, in the third quarter of 2009.

28 Oct 2010

Octapharma initiates Human-cl rhFVIII clinical study for severe hemophilia A

Octapharma, one of the largest human protein products manufacturers in the world, today announced that patients diagnosed with severe hemophilia A have started treatment with the first recombinant Factor VIII derived from a human cell line (Human-cl rhFVIII). Researchers are investigating pharmacokinetics, efficacy, safety and immunogenicity of Human-cl rhFVIII for previously treated patients with severe hemophilia A.

28 Oct 2010

Scientists suggest FDA to reevaluate safety of plant-based antioxidants

Scientists are calling for more research on the possibility that some supposedly healthful plant-based antioxidants including those renowned for their apparent ability to prevent cancer may actually aggravate or even cause cancer in some individuals.

28 Oct 2010

Systemic amyloidosis patient to receive triple organ transplant

In 2005, then 40-year-old Walt McGuire was playing hockey twice a week, working full-time and chasing his young daughter. Then one day, he noticed after one trip up the stairs to catch her, he couldn't catch his breath. A few days later his legs were swollen. After numerous trips to different doctors, McGuire finally was diagnosed with a rare blood disorder called amyloidosis.

28 Oct 2010

More research needed on impact of exercise on hypertensive patients

There are many good reasons to ensure sufficient exercise in everyday life. However, advising patients with increased blood pressure (hypertension) to exercise regularly is often regarded as a specific medical measure aiming to reduce the increased risk of late complications. But whether more exercise actually helps to avoid illnesses related to hypertension or at least delay their onset has been insufficiently investigated.

27 Oct 2010

Rockwell receives SFP patent for GMP formulation

Rockwell Medical a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron deficiency anemia, announced today that it has received notice from the U.S. Patent and Trademark Office for patent issuance on its proprietary GMP formulation for Soluble Ferric Pyrophosphate (SFP), the Company's lead-drug candidate for treating iron deficiency anemia in ESRD patients.

27 Oct 2010